Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET

To reduce doxorubicin, bleomycin, vinblastine and dacarbazine toxicity, the Cancer and Leukemia Group B conducted a phase 2 trial of doxorubicin, vinblastine, and gemcitabine for newly diagnosed, nonbulky stages I and II Hodgkin lymphoma. Ninety-nine assessable patients received 6 cycles of doxorubi...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Straus, David J., Johnson, Jeffrey L., LaCasce, Ann S., Bartlett, Nancy L., Kostakoglu, Lale, Hsi, Eric D., Schöder, Heiko, Hall, Nathan C., Jung, Sin-Ho, Canellos, George P., Schwartz, Lawrence H., Takvorian, Ronald W., Juweid, Malik E., Cheson, Bruce D.
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society of Hematology 2011
Materias:
Clinical Trials and Observations
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3109706/
https://ncbi.nlm.nih.gov/pubmed/21355087
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2010-10-314260
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares